Promis Neurosciences Inc.: 5%+ holders

As of November 6, 2026, 10 holders' latest Schedule 13D or 13G filings report owning 5% or more of Promis Neurosciences Inc. The largest reported stake is ABG Management Ltd.'s, at 17%. 24 filings are on record since July 31, 2025 (Schedule 13D/A, February 5, 2026).

Who owns ProMIS Neurosciences Inc.?

ABG Management Ltd. also filed stake reports on 2 other companies ↓

Sell to companies like Promis Neurosciences Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filing 2026-08-14 · Reporting person: Great Point Partners, LLC · Sole voting: 0 · Shared voting: 736,881 · Sole dispositive: 0 · Shared dispositive: 736,881 · SCHEDULE 13G/A, 2026-08-14
• Filing 2026-08-13 · Reporting person: Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. · Sole voting: 0 · Shared voting: 696,378 · Sole dispositive: 0 · Shared dispositive: 696,378 · SCHEDULE 13G/A, 2026-08-13
• Filing 2026-08-13 · Reporting person: Wellington Management Group LLP · Sole voting: 0 · Shared voting: 696,378 · Sole dispositive: 0 · Shared dispositive: 696,378 · SCHEDULE 13G/A, 2026-08-13
• Filed 2026-05-15 · Holder: Wellington Management Group LLP · Percent: 10% · SCHEDULE 13G
• Filed 2026-05-15 · Holder: Great Point Partners, LLC · Percent: 9.99% · SCHEDULE 13G

Promis Neurosciences Inc. has 24 Schedule 13D or 13G filings on record since 2025-07-31. 10 holders' latest filing reports 5% or more of common shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Promis Neurosciences Inc. and the warning signs.

See Promis Neurosciences Inc.'s free Snapshot Watch Promis Neurosciences Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Promis Neurosciences Inc. and the records around it.

Promis Neurosciences Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• ABG Management Ltd. also filed stake reports on 2 other companies: Whitehawk Therapeutics, Inc. (Aug 2026), Ceribell, Inc. (Dec 2025)
• Sphera Funds Management Ltd. also filed stake reports on 2 other companies: Tenax Therapeutics, Inc. (Oct 2026), Outlook Therapeutics, Inc. (Feb 2026)
• Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. also filed stake reports on 2 other companies: Korsana Biosciences, Inc. (Sep 2026), MBX Biosciences (Nov 2025)

Want the whole picture on Promis Neurosciences Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on Promis Neurosciences Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Promis Neurosciences Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   24 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Promis Neurosciences Inc. by CUSIP 74346M505 and gives its principal executive office as Suite 200, 1920 Yonge Street, Toronto (SCHEDULE 13G/A, 2026-08-14).

Purpose of Transaction (Item 4)

ABG Management Ltd.

Item 4 is amended and supplemented by the following: CLOSING OF OFFERING On February 3, 2026, the previously disclosed Offering closed. REGISTRATION RIGHTS AGREEMENT On February 3, 2026, in connection with the closing of the Offering, the Issuer entered into a registration rights agreement (the "2026 Registration Rights Agreement") with the investors in the Offering, pursuant to which the Issuer is required to prepare and file a registration statement with the Securities and Exchange Commission covering the resale of the Common Shares issued to the investors pursuant to the Securities Purchase Agreement, together with the Common Shares underlying the Warrants. The foregoing description of the 2026 Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the form-of 2026 Registration Rights Agreement, which is attached as an exhibit to this Schedule 13D and incorporated herein by reference. REVERSE STOCK SPLIT The amount of Common Shares reported herein reflects a 1-for-25 reverse stock split that occurred on November 28, 2025.Item 4 of the SCHEDULE 13D/A filed 2026-02-05

Timeline

Swipe the table sideways to see every column.

Questions about who owns Promis Neurosciences Inc.

Who owns Promis Neurosciences Inc.?

On this page, 10 holders' latest ownership filings report 5% or more of Promis Neurosciences Inc.: ABG Management Ltd. (17%, Schedule 13D/A, filed 2026-02-05), Jeremy M. Sclar (16.9%, Schedule 13G/A, filed 2025-10-15), Janus Henderson Group Plc (14.4%, Schedule 13G, filed 2026-04-07), Shaf QIC LLC (10.01%, Schedule 13G/A, filed 2025-07-31) and Deep Track Capital, LP (9.99%, Schedule 13G, filed 2026-02-06); 5 more are listed above.

Who are the largest shareholders of Promis Neurosciences Inc.?

By the share each holder's latest filing reports, the largest holders of Promis Neurosciences Inc. on this page are ABG Management Ltd. (17%), Jeremy M. Sclar (16.9%) and Janus Henderson Group Plc (14.4%).

When did ABG Management Ltd. buy into Promis Neurosciences Inc.?

The filings give report dates, not purchase dates. The earliest filing from ABG Management Ltd. on this page is the Schedule 13G, filed 2025-08-04, reporting 11.8%; its latest, Schedule 13D/A filed 2026-02-05, reports 17%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 24 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Tools for this story

Each opens in a new tab, filled in for Promis Neurosciences Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Promis Neurosciences Inc. is mentioned again
• Find former Promis Neurosciences Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes